Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9–14-year-old and 18–26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial-Reference-Cited by-同舟云学术

Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9–14-year-old and 18–26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial

Published:2023-11 Issue:48 Volume:41 Page:7212-7219
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Li Juan,Shi Li-Wei,Li Ke,Huang Li-Rong,Li Jian-Biao,Dong Yu-Lian,Li Wei,Ji Min,Yang Qing,Zhou Ling-Yun,Yuan Lin,Yan Xue-Mei,Chen Jing-Jing^ORCID,Jiang Zhi-Wei,Qi Yang-Yang,Li Rong-Cheng,Li Yan-Ping,Xia Jie-Lai,Yu Bang-Wei,Mo Zhao-Jun,Li Chang-Gui

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference21 articles.

1. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study;Xia;Lancet Public Health,2019

2. China: Human papillomavirus and related cancers, Fact Sheet 2021 (22/10/2021). Available at: https://hpvcentre.net/datastatistics.php [accessed on October 9, 2023].

3. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis;Zou;Lancet Glob Health,2020

4. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9–45 years: a randomized double-blind placebo-controlled phase 1 clinical trial;Li;Vaccine,2023

5. Safety and immunogenicity of a novel bivalent HPV16/18 vaccine in Chinese females;Shi;Hum Vaccin Immunother,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future directions for the development of human papillomavirus vaccines;Frontiers in Immunology;2024-06-25